RecruitingNot ApplicableNCT03504956

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

Sponsor

Cedars-Sinai Medical Center

Enrollment

150 participants

Start Date

Jul 30, 2018

Study Type

INTERVENTIONAL

Conditions

Coronary atherosclerosis

Summary

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Beta blocker, a medical device called Cardiac MRI, and others for people with coronary atherosclerosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICECardiac MRI

MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.

DRUGContrast

The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).

DRUGBeta blocker

Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.